Explanipedia

Serum NF-κB-Regulated Biomarkers of Proliferative Lupus Nephritis Open

Nicholas A. Shoctor, Makayla Brady, Rebecca Lightman, Kristen Overton, Shweta Tandon , et al. · 2025

Introduction: Lupus nephritis (LN) is kidney inflammation that commonly occurs from systemic lupus erythematosus. NF-κB activity is increased in LN patients, leading to elevated circulating concentrations of immune modulators that contribu…

Increased Urine Excretion of Neutrophil Granule Cargo in Active Proliferative Lupus Nephritis Open

Nicholas A. Shoctor, Makayla Brady, Kenneth R. McLeish, Rebecca Lightman, Leshaia Davis-Johnson , et al. · 2024

Key Points Neutrophil degranulation participates in glomerular injury in proliferative lupus nephritis. Urine excretion of neutrophil granule proteins is a potential diagnostic for proliferative lupus nephritis. Background Lupus nephritis …

Corrigendum to “Clinicopathological Characteristics of Adult IgA Nephropathy in the United States” [Kidney International Reports Volume 8, Issue 9, September 2023, Pages 1792-1800] Open

Dawn J. Caster, Clint W. Abner, Patrick D. Walker, Kaijun Wang, Jihaeng Heo , et al. · 2023

Management of Lupus Nephritis: New Treatments and Updated Guidelines Open

Rupali S. Avasare, Yelena Drexler, Dawn J. Caster, Alla Mitrofanova, J. Ashley Jefferson · 2023

Management of lupus nephritis has evolved considerably over the past years. Here, we provide a comprehensive review of clinical trials that form the basis for the Kidney Disease: Improving Global Outcomes and EULAR/ERA-EDTA updated guideli…

Table of Contents Open

Mohammed Hassanein, Laurence H. Beck, Isabelle Ayoub, Dawn J. Caster, Michael Choi , et al. · 2023

Safety and Efficacy of Long‐Term Voclosporin Treatment for Lupus Nephritis in the Phase 3 AURORA 2 Clinical Trial Open

Amit Saxena, Ellen M. Ginzler, Keisha Gibson, Bancha Satirapoj, Adolfina Elizabeth Zuta Santillán , et al. · 2023

Objective AURORA 2 evaluated the long‐term safety, tolerability, and efficacy of voclosporin compared to placebo in patients with lupus nephritis (LN) receiving an additional two years of treatment following completion of the one‐year AURO…

Clinicopathological Characteristics of Adult IgA Nephropathy in the United States Open

Dawn J. Caster, Clint W. Abner, Patrick D. Walker, Kaijun Wang, Jihaeng Heo , et al. · 2023

Most patients with IgAN in our US cohort were diagnosed at CKD stage ≥3 and had high MEST-C scores and proteinuria that are suggestive of significant disease burden at the time of kidney biopsy. Strategies are required to raise awareness a…

Update on the Efficacy and Safety Profile of Voclosporin: An Integrated Analysis of Clinical Trials in Lupus Nephritis Open

Cristina Arriens, Y K Onno Teng, Ellen M. Ginzler, Samir V. Parikh, Anca Askanase , et al. · 2022

Objective This integrated analysis evaluates the efficacy and safety of voclosporin, a novel calcineurin inhibitor, at 23.7 mg twice daily in combination with mycophenolate mofetil (MMF) and oral glucocorticoids in lupus nephritis (LN) usi…

A Case of Colon Cancer and Pauci-Immune Crescentic Glomerulonephritis Open

David Wilhelm, Dawn J. Caster, Susan Coventry, Gunjan Garg · 2022

Efficacy and Safety of Immunosuppressive Therapy in Primary Focal Segmental Glomerulosclerosis: A Systematic Review and Meta-analysis Open

Dawn J. Caster, Bárbara Magalhães, Natali Pennese, Andrea Zaffalon, Marina Faiella , et al. · 2022

This systematic review supports proteinuria reduction with immunosuppressant therapy in primary FSGS over varying follow-up periods. The effects of immunosuppressants on kidney survival remain uncertain. This review underscores the need fo…

Serum and Urine Interferon Gamma-Induced Protein 10 (IP-10) Levels in Lupus Nephritis Open

Makayla Brady, Saiteja Chava, Shweta Tandon, Madhavi J. Rane, Michelle T. Barati , et al. · 2022

Background: Lupus nephritis (LN) is a prevalent and severe complication of systemic lupus erythematosus (SLE). Non-invasive diagnostics are limited, and current therapies have inadequate response rates. Expression of the chemokine Interfer…

Efficacy and Safety of ACE Inhibitor and Angiotensin Receptor Blocker Therapies in Primary Focal Segmental Glomerulosclerosis Treatment: A Systematic Review and Meta-Analysis Open

Kirk N. Campbell, Natali Pennese, Andrea Zaffalon, Bárbara Magalhães, Marina Faiella , et al. · 2022

This review supports the tendency to observe a proteinuria reduction with RAAS inhibitors in patients with primary FSGS. RAAS inhibitor monotherapy was associated with maintained kidney function, as shown by no change in creatinine clearan…

The Potential of Nrf2 Activation as a Therapeutic Target in Systemic Lupus Erythematosus Open

Michelle T. Barati, Dawn J. Caster · 2022

Inflammation and oxidative stress are well established in systemic lupus erythematosus (SLE) and are critical to the pathogenesis of autoimmune diseases. The transcription factor NF-E2 related factor 2 (Nrf2) is a central regulator of cell…

Quantitative Mass Spectrometry Normalization in Urine Biomarker Analysis in Nephrotic Syndrome Open

Timothy D. Cummins, David W. Powell, Daniel W. Wilkey, Makayla Brady, F. Benz , et al. · 2022

Chronic kidney disease (CKD) affects 30 million adults, costs ∼$79 billion dollars (2016) in Medicare expenditures, and is the ninth leading cause of death in the USA. The disease is silent or undiagnosed in almost half of people with seve…

A Core Outcome Set for Trials in Glomerular Disease Open

Simon Carter, Liz Lightstone, D C Cattran, Allison Tong, Arvind Bagga , et al. · 2021

Background and objectives Outcomes reported in trials in adults with glomerular disease are often selected with minimal patient input, are heterogeneous, and may not be relevant for clinical decision making. The Standardized Outcomes in Ne…

A Focus Group Study of Self-Management in Patients With Glomerular Disease Open

Simon Carter, Claris Teng, Talia Gutman, Charlotte Logeman, D C Cattran , et al. · 2021

Patients with glomerular disease and their care partners value their capacity for autonomy and disease ownership, stability of their health, and relationships that support self-management. Strategies directed at strengthening these factors…

Collagen Remodeling Biomarkers in Lupus Nephritis Open

Dawn J. Caster, Michael L. Merchant · 2021

The extracellular matrix (ECM) is a complex network of collagens, elastin, and interconnecting glycoproteins and proteoglycans that surround cells and provide structural support. The ECM is a dynamic structure, undergoing constant remodeli…

Integrin CD11b Negatively Regulates B Cell Receptor Signaling to Shape Humoral Response during Immunization and Autoimmunity Open

Mingqian Zhou, Paul Dascani, Chuanlin Ding, Justin T. Kos, David Tieri , et al. · 2021

Our previous work has revealed the ability of CD11b to regulate BCR signaling and control autoimmune disease in mice. However, how CD11b regulates the immune response under normal conditions remains unknown. Through the use of a CD11b knoc…

Patients with Proliferative Lupus Nephritis Have Autoantibodies That React to Moesin and Demonstrate Increased Glomerular Moesin Expression Open

Dawn J. Caster, Erik A. Korte, Michael L. Merchant, Jon B. Klein, Michelle T. Barati , et al. · 2021

Kidney involvement in systemic lupus erythematosus (SLE)—termed lupus nephritis (LN)—is a severe manifestation of SLE that can lead to end-stage kidney disease (ESKD). LN is characterized by immune complex deposition and inflammation in th…

Management and treatment of glomerular diseases (part 2): Conclusions From A Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference Open

Brad H. Rovin, Dawn J. Caster, Daniel C. Cattran, Keisha Gibson, Jonathan J. Hogan , et al. · 2021

In November 2017, the Kidney Disease: Improving Global Outcomes (KDIGO) initiative brought a diverse panel of experts in glomerular diseases together to discuss the 2012 KDIGO glomerulonephritis guideline in the context of new developments…

Spectrum of Kidney Diseases in Patients With Hepatitis C Virus Infection Open

Shunhua Guo, Meghan Kapp, Diego M Beltran, Cesar Y. Cardona, Dawn J. Caster , et al. · 2020

Objectives To study the pathologic spectrum of kidney diseases in patients with hepatitis C virus infection (HCV+). Methods Native kidney biopsy specimens in HCV+ patients were reviewed. Results A total of 9,836 native kidney biopsy specim…

TNIP1/ABIN1 and lupus nephritis: review Open

Makayla Brady, Erik A. Korte, Dawn J. Caster, David W. Powell · 2020

SLE is a complex autoimmune disease with genetic, epigenetic, immune-regulatory, environmental and hormonal factors. Kidney inflammation and injury, termed lupus nephritis (LN), occurs in over half of patients with SLE and is a leading cau…

Proteomic Analysis Identifies Distinct Glomerular Extracellular Matrix in Collapsing Focal Segmental Glomerulosclerosis Open

Michael L. Merchant, Michelle T. Barati, Dawn J. Caster, Jessica Hata, Liliane Hobeika , et al. · 2020

Significance Statement Extracellular matrix (ECM) replaces glomerular capillaries in FSGS. To evaluate differences in ECM remodeling between collapsing FSGS (cFSGS) and FSGS not otherwise specified (FSGS-NOS), we performed a proteomic anal…

Identifying Outcomes Important to Patients with Glomerular Disease and Their Caregivers Open

Simon Carter, Talia Gutman, Charlotte Logeman, D C Cattran, Liz Lightstone , et al. · 2020

Background and objectives Shared decision making in patients with glomerular disease remains challenging because outcomes important to patients remain largely unknown. We aimed to identify and prioritize outcomes important to patients and …

Precision Targeting of NF-κB Signaling in Lupus Nephritis. Open

Dawn J. Caster, David W. Powell · 2020

Lupus Nephritis (LN) is the leading cause of morbidity and mortality from Systemic Lupus Erythematosus (SLE) and enhanced activation of the transcription regulator nuclear factor kappa B (NF-κB) is implicated as a central player in the dev…

Utilization of Biomarkers in Lupus Nephritis Open

Dawn J. Caster, David W. Powell · 2019

Standardized Outcomes in Nephrology—Glomerular Disease (SONG-GD): establishing a core outcome set for trials in patients with glomerular disease Open

Simon Carter, Liz Lightstone, Daniel Cattran, Arvind Bagga, Sean J. Barbour , et al. · 2019

Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference Open

Brad H. Rovin, Dawn J. Caster, Daniel C. Cattran, Keisha Gibson, Jonathan J. Hogan , et al. · 2019

Table of Contents Open

Deidra C. Crews, Aminu K. Bello, Gamal Saadi, A. Richard Kitching, Stephen R. Holdsworth , et al. · 2019

Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference Open

Jürgen Floege, Sean Barbour, Daniel Cattran, Jonathan J. Hogan, Patrick H. Nachman , et al. · 2019

Dawn J. Caster YOU? Author Swipe